# Effects of Intranasal Oxytocin on Satiety Signaling in People With Schizophrenia

> **NCT01614093** · PHASE4 · COMPLETED · sponsor: **University of Maryland, Baltimore** · enrollment: 24 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Oxytocin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01614093
- **Lead sponsor:** University of Maryland, Baltimore
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2014-01
- **Final completion:** 2014-01
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2019-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01614093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01614093, "Effects of Intranasal Oxytocin on Satiety Signaling in People With Schizophrenia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01614093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*